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Summary Human papillomavirus (HPV) typing and quantitation by polymerase chain reaction was per-
formed on exfoliated cells from 133 women referred for colposcopy because of an abnormal smear. High levels
of HPV 16 correctly predicted cervical intraepithelial neoplasia (CIN) grade II-III in 93% of its occurrences,
but only 59% of cases of CIN III were associated with high levels of this type. Eighty-four per cent of CIN III
lesions contained high levels of at least one of HPV types 16, 18, 31, 33 and 35, but the other types were less
specific for CIN III than HPV 16. Overall HPV testing compared favourably with cytology for predicting
high-grade CIN lesions, but it would appear that some combination of the two modalities will produce better
performance than either alone. In particular, HPV testing appears to be helpful in determining which women
with mildly abnormal smears have high-grade underlying lesions in need of immediate referral for colposcopy.
Cytological screening for cervical dysplasia is an effective
method of reducing the incidence of and mortality from
cervix cancer (Hakama, 1982; IARC Working Group, 1986;
Laara et al., 1987; Hakama et al., 1991). However, it is not a
perfect screening method and suffers from several problems.
A major problem is how to deal with the large number of
borderline and mildly dyskaryotic smears which have a
highly variable underlying pathology. On biopsy about a
third of these smears are found to arise from major grade
lesions (CIN II/III), another third have CIN I lesions and the
remainder are normal or show very minor changes. Cytology
also misses lesions, especially smaller lesions (Barton et al.,
1989; Szarewski et al., 1991). Possibly these can be safely left
until the next routine smear, but invasive cancer can also be
missed (Mitchell et al., 1990). Lastly, on the scale practised
today, cytological examination of slides for dyskaryotic
changes is a time-consuming, tedious and eye-fatiguing
activity leading to difficulty in recruiting and keeping staff,
and making the cost-effectiveness of the programme less
favourable than it might be.
In the past two decades much effort has been devoted
towards trying to automate and simplify the preparation and
reading of smears, and several prototype computer-assisted
screening systems are under evaluation (Banda-Gamboa et
al., 1992). However, none is currently in routine use, and
interest in alternative or complementary modalities is high.
The most thoroughly evaluated among these is cervicography
(Stafl, 1981; Tawa et al., 1988; Szarewski et al., 1991), which
is highly sensitive but does not appear to be sufficiently
specific. However, the possibility that has stimulated the most
interst is the detection and typing of HPV DNA in exfoliated
cervical cells (Bauer et al., 1991; Schiffman et al., 1991; van
den Brule et al., 1991; Koutsky et al., 1992). Using modern
polymerase --chain reaction (PCR)-based methods, several
recent studies have found an extremely strong association
between high-risk types of HPV and cervical cancer (Mufioz
& Bosch, 1992; Munioz et al., 1992). However, some inves-
tigators (Meanwell et al., 1987; Young et al., 1989) have
observed a high proportion of HPV-positive smears in the
normal population, and this has raised doubts as to its
usefulness in a screening context. One explanation for this is
the extreme sensitivity and proneness to contamination of the
PCR assay method, which is capable of detecting extremely
small amounts of HPV DNA (Gravitt & Manos, 1992).
These very low levels of virus appear to be common and may
not be related to disease. In a previous report (Cuzick et al.,
1992a) we emphasised the need for some form of
quantification of the amount of HPV DNA present. In that
study we found that a high level of HPV 16 DNA in an
abnormal smear of any grade was an extremely specific
indication of an underlying CIN III lesion. However, its
sensitivity was only 63%, suggesting that in the remaining
cases other HPV types were involved, or possibly that
CIN III could be present in an important fraction of cases,
without the existence of a concurrent high-level HPV infec-
tion. Recently Bavin et al. (1993) have confirmed the value of
HPV 16 DNA testing for identifying high-grade disease in
women with mildly dyskaryotic smears.
In this paper we extend that report by increasing the
number of women studied and by looking individually at
several HPV types. The specific aim was to examine the value
of HPV typing for deciding which women with mild cervical
abnormalities detected by cytology actually harbour a high-
grade (CIN II/III) lesion and are in need of immediate refer-
ral for colposcopy. We also wished to examine the relative
value of the different HPV types in predicing high-grade
disease. The use of HPV DNA detection, typing and
quantification in primary screening will not be addressed here
and is the subject of several large ongoing studies.
Patients and methods
Patients referred for colposcopy were studied. In most cases
the referral was based on current British guidelines, i.e. a
single moderate or severely dyskaryotic smear or a persistent
mild abnormality. Eleven women were also included whose
smears showed at most borderline changes but who were
referred because of other symptoms.
At the time of colposcopy, another smear was taken with
an Ayre spatula and sent for routine cytological assessment.
The same spatula was used to collect additional cells, which
were then agitated into phosphate-buffered saline and stored
at - 20°C. Any areas of abnormal epithelium found on
colposcopy were biopsied (punch biopsy, loop diathermy, or
laser cone, as appropriate), and sent for routine histological
examination. Women with no colposcopically visible abnor-
mality were not biopsied and were assumed to be histo-
logically normal.
The semiquantitative PCR method was carried out as
previously described (Terry et al., 1993). Briefly, after thaw-
ing, exfoliated cells were pelleted and washed twice. Cell
pellets were digested with SDS (0.5%) and proteinase K
(500 psg ml-') for 6 h or overnight at 37°C and extracted
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twice with phenol/chloroform and once with chloroform.
After ethanol precipitation, the pellets were washed once with
70% ethanol, resuspended in 10 mM Tris (pH 8.0) and 1 mM
EDTA (TE) and digested with RNAse (100 utg ml-') for 1 h
at 37°G. After re-extraction (once with phenol, once with
phenol/chloroform and once with chloroform) the DNA was
precipitated, washed with 70% ethanol and dissolved in 50 ul
of TE. The amount of DNA recovered from each specimen
was determined by spotting 1 ftl of serial dilutions on a
commercially available dipstick (Invitrogen).
Separate PCR reactions were run for each of the HPV
types 6/11, 16, 18, 31, 33, 35 using the primers and annealing
temperatures shown in Table I. PCR reactions were con-
ducted in 50ptl containing 100 ng of specimen DNA, 10 mM
Tris-HCI pH 8.3 (at 25°C), 50 mM potassium chloride,
1.5mM magnesium chloride, 0.01% gelatin and 50pmol of
each primer. AmpliTaq polymerase (Perkin Elmer Cetus) was
added at 70'C after the initial denaturation (1.25 units).
Amplification was for 35 cycles of (i) denaturation at 94'C
for 15 s, (ii) annealing for 15 s at the temperatures given in
Table I and (iii) extension at 72'C for 30 s, with a final
extension at 72'C for 8 min.
The PCR products were located by ethidium bromide
staining after electrophoresis on a 2% agarose gel. Reactions
containing 0.4, 2, 10 and 100 fg of type-specific HPV DNA
from a standard preparation and 100 ng of human DNA
were included in every PCR run. The levels of HPV DNA in
individual test specimens were estimated visually by com-
parison with the standards. These were considered 'high' if
the band intensity was equal to or greater than the 100-fg
standard, 'intermediate' if the band intensity was between the
100-fg and the 2-fg standards, 'low' if a band was visible but
the intensity was equal to or below the 2-fg standard and
'negative' if no band was visible. For the purposes of this
analysis 'high' and 'intermediate' results were combined and
labelled 'high'. All assays were performed and scored without
knowledge of the cytology or histology results. A represen-
tative series of runs is shown in Figure 1.
The PCR primers used in this study were chosen from the
literature to be type specific. This was confirmed using cloned
HPV plasmids and by the results obtained on clinical speci-
mens which contained very high levels of only one of the
tested HPV types. Many specimens have also been tested
using alternative type-specific primer pairs and give entirely
consistent results with those presented here.
Both CIN II and CIN III have been used for computing
positive predictive values (PPVs), whereas only CIN III has
HPV 16 primers 228-bp product
HPV 33 primers347-bp product
HPV 31 primers 109-bp product
HPV 18 primers 405-bp product
18 specimens Four standards
i100 10 2.0 and 0.4fg of HPV DNA
No DNA control
Figure 1 Composite photograph of four PCR runs showing
bands for HPV types 16, 18, 31 and 33 for 18 specimens, four
standards and a negative control.
been used for computing sensitivity. This seems appropriate
here, since it is useful to pick up CIN II, but missing it is not
so critical as missing CIN III. This will give better figures
than using either CIN II/III or CIN III alone for both
measures, but neither of these conventions appears parti-
cularly helpful. However, if desired, the relevant measures
can be computed from Table III.
Results
A total of 133 women were studied, including 87 women on
whom we have previously reported results for HPV 16 alone
(Cuzick et al., 1992a). The relationship between referring
ctyology grade and histological diagnosis is shown in Table
II. The mean age was 32 years and was similar for all
cytological and pathological subgroups (always within 2
Table I Type-specific primers used in the PCR reaction and anealing temperatures
Annealing
temperature
Type Primer and reference Location (nt) (OC)
HPV 6/11 HPV 6b sense: 5'-GCAGCCTGCGCGTGCTGCCTAG-3' 285-306 65
Schwarz et al. (1983)
HPV 11 sense: 5'-GCCTCCACGTCTGCAACATC-3' 117-136
Dartmann et al. (1986)
HPV 6/11 antisense: 5'-CTTCCATGCATGTTGTCCAG-3' 540-521
HPV 16 Sense: 5'-AAGGCCAACTAAATGTCAC-3' 7763-7781 54
Antisense: 5'-(GCGGATCC)TGTCTGCTTTTATACTAA-3' 78-61
Seedorf et al. (1985) (+5' BamHI
site)
HPV 18 Sense: 5'-CACGGCGACCCTACAAGCTACCTG-3' 127-150 70
Antisense: 5'-TGCAGCACGAATGGCACTGGCCTC-3' 531-508
Coles and Danos (1987)
HPV 31 Sense: 5'-AGAAAGACCTCGGAAATTG-3' 125-143 54
Antisense: 5'-TACCTCTGTTTCTGTTAAC-3' 233-215
Goldsborough et al. (1989)
HPV 33 Sense: 5'-CTACAGTGCGTGGAATGCAAAAAACC-3' 190-215 65
Antisense: 5'-CGGGACCTCCAACACGCCGCAC-3' 536-515
Cole and Streeck (1986)
HPV 35 Sense: 5'-ACAAGAATTACAGCGGAG-3' 211 -228 50
Antisense: 5'-TAACTGTTTGTTGCATTGT-3' 397-379
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years of this value). All specimens contained amplifiable
DNA when tested using ,B-globin PCR primers. Only one
HPV 6-positive patient was found, and she had a history of
condyloma acuminatum. No cases of HPV 11 infection were
detected. The relationship of the remaining types to histo-
logical diagnosis is shown in Table III. Since the relationship
between HPV and histological diagnosis did not appear to be
related to the grade of referral cytology (see Table V for
HPV 16), to simplify presentation all cytological categories
have been combined. It can be seen from Table III that
HPV 16 infection was by far the most common and that high
levels were very predictive for CIN II/III, this being diag-
nosed in 93% (39/42) of the patients in whom high-level
HPV 16 was present. However, only 59% (36/61) of CIN III
cases were associated with high levels of HPV 16 and only
67% (41/61) were associated with any detectable level of
HPV 16.
Table II Relationship between referring cytology and histological
diagnosis
Cytological diagnosis
Borderline
Histological inflamed or
diagnosis Severe Moderate Mild normal Total
CIN III 26a 24 10 1 61
CIN II 3 7 2 0 12
CIN I 2 6 3 2 13
HPV 1 2 7 0 2 11
Normal 5 9 16 6 36b
Total 38 53 31 11 133
aIncludes two cases ofinvasive cancer. bIncludes 12 women with no
visible lesion on colposcopy who were not biopsied.
The next most prevalent type was HPV 31, and 70% (14/
20) of the high-level cases were associated with CIN II/III.
Five of these were double infections also containing HPV 16,
so nine cases were newly detected. Low levels of HPV 31 also
appeared to predict CIN III well (five of six cases), although
three of these were double infections with a high level of
another type (16, 33, 35, once each). It is possible that a
lower threshold for 'high level' of HPV 31 would improve its
performance, but this point requires further investigation.
Eleven of 16 women with high levels of HPV 33 had CIN II/
III, but six of them had multiple infections (always contain-
ing HPV 16), so only five cases were newly detected. High
levels of HPV 18 were found in nine patients, and six of them
had CINII/III (PPV 67%). Three of these six cases were
double infections with HPV 16, and the other three contained
only HPV 18.
High levels of HPV 35 were detected in only four patients,
but two of them had CIN III. Both women had no other
HPV types, but the remaining two 'normal' women had
double high-level infections (one HPV 16, one HPV 18).
Altogether 84% (51/61) of CIN III lesions had high levels
of one of these HPV types and 95% had detectable amounts
of one of these types. However, including further types
reduces the specificity of the test. For lesions which were
CIN I or less, 25% contained a high level of some type and
45% contained detactable levels of some type. In Table IV
the positivity rates for various combinations of HPV types
and cytology are related to histological outcome, and the
PPV for CIN II/III and sensitivity in predicting CIN III are
given. High levels of HPV 16 were more predictive of high-
grade disease and more sensitive than severe dyskaryosis, but
a combination of cytology and HPV measurements appeared
to be better than either alone. For example, very good per-
formance was seen for the grouping 'high HPV 16, any
HPV 31 or severe dyskaryosis', where the PPV for CIN II/III
Table III Number of patients with high and low levels of specific HPV types by histological diagnosis
HPVpositivity and level
No. of HPV 16 HPV18 HPV31 HPV33 HPV35
Histology patients Low High Low High Low High Low High Low High
CIN III 61 5 (1) 36 (10) 8 (6) 4 (2) 5 (3) 14 (5) 1 (0) 7 (5) 0 2 (0)
CIN II 12 2 (1) 3 (2) 1 (0) 2 (1) 0 0 0 4 (1) 0 0
CINI 13 3 (1) 0 3 (2) 0 1 (0) 3 (0) 2 (0) 1 (0) 1 (0) 0
HPV I 11 2 (0) 1 (1) 0 0 0 2 (1) 0 2 (2) 0 0
Normal 36 4 (1) 2a (1) 3 (1) 3 (1) 0 1 (0) 1 (0) 2 (0) 0 2 (2)
Total 133 16 (4) 42 (14) 15 (9) 9 (4) 6 (3) 20 (6) 4 (0) 16 (8) 1 (0) 4 (2)
Numbers in parentheses indicate the number with multiple infections, where the other type(s) were 'high level'. Multiple
infections are included for each positive type and thus are represented at least twice in the table. aOne patient was pregnant.
TableIV Histological diagnosis fordifferent subsetsofpatientsdivided according to HPVtypeand
cytology
Number of women positive by histological Positive
diagnosis predictive Sensitivity
Test criterion <CIN CINI CINII CINIII value (%) (%)
High HPV 16 3 0 3 36 93 59
Any HPV 16 9 3 5 41 79 67
High HPV 16 or high 6 3 3 45 84 74
HPV 31
High HPV 16 or any 6 4 4 48 84 79
HPV 31
High HPV 16 or severe 9 2 5 47 83 77
dyskaryosis
High HPV 16, any 11 5 5 56 79 92
HPV 31 or severe
dyskaryosis
Any high HPV 11 4 7 51 79 84
Any HPV 17 10 9 58 71 95
Severe dyskaryosis 7 2 3 26 76 43
Moderate or severe 23 8 10 50 66 82
dyskaryosis
All patients 47 13 12 61 55 100
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Table V Relationship between histology and a high level of HPV 16 on the smear according to
referring cytology grade
Number ofwomen positive by histological High-level HPV 16
Referring diagnosis Positive predic- Sensitivity
cytology No. <CIN CIN I CIN II CIN III tive value (%) (%)
Severe 38 1 0 1 15 94 58
Moderate 53 1 0 1 15 94 63
Mild 31 0 0 1 6 100 60
Borderline or 11 1 0 0 0 - -
less
All 133 3 0 3 36 93 59
Positive predictive value refers to CIN II/III, whereas sensitivity is for CIN III.
Table VI Mean age and percentage current smokers according to
HPV 16 level
HPV 16 level No. Age (years) Current smokers (%)
Negative 75 32.4 44.0
Low 16 33.9 43.8
High 42 28.8 57.1
was 79% and the sensitivity for CIN III was 92%. However
these results are based on a data-dependent discriminant and
need to be verified on an independent sample.
HPV 16 is clearly the single most important type for pre-
dicting high-grade disease, and we have examined its rela-
tionship to other factors in greater detail. To illustrate that
its predictive value was not appreciably influenced by grade
of cytological abnormality, the results are presented by
cytological grade in Table V. Table VI shows that women
with high levels of HPV 16 were slightly younger than those
with low levels or no detectable amount. Also, 57% of these
women were current smokers compared with 44% of the
remaining women. Smokers were also over-represented
among women with high-grade disease (55%, 50% and 41%
respectively for women with CIN III, CIN II and CIN I or
less) or with high-grade smears (61%, 42%, 52%, 27%
respectively for severe, moderate, mild and borderline or less
dyskaryosis).
Discussion
Much uncertainty exists regarding the appropriate manage-
ment ofwomen with mildly abnormal smears. This study was
conducted among an unselected group of women referred for
colposcopy because of an abnormal smear. We found that
high levels of HPV 16 in the smear almost always predicted
CIN II/III lesions, whereas low-level infections were not help-
ful in this regard. Similar results have also been found in
cervical biopsies (Terry et al., 1993). The results were similar
for all grades ofcytological referral, suggesting that they may
also be applicable to women with a single mildly dyskaryotic
smear, and that a high level of HPV 16 in the presence of
any degree of dyskaryosis is grounds for immediate referral
for colposcopy. Recent results from Bavin et al. (1993) also
support this view. However, the lack of high levels of
HPV 16 did not indicate the absence of high-grade disease,
since this was found in about 40% of the CIN III patients.
Many of these (11/25) had severe dyskaryosis, which is also a
clear sign for immediate referral. The other HPV types were
helpful in picking up the remainder, but they were not so
specific and their value in augmenting cytology for borderline
and mild disease is less clear. In this regard HPV 31 appeared
to be the most useful, but larger studies will be needed to
clarify this question. Our data also suggest that a lower
threshold may be appropriate for HPV 31, but again further
experience is needed here.
The PPV for HPV 18 was similar to that for HPV 31 and
HPV 33 but lower than that for HPV 16. This is somewhat
surprising given its high oncogenic potential (Lorincz et al.,
1992). In view of its relative rarity and the moderate sample
size available, this could be a chance observation. However,
HPV 18 is associated with endocervical lesions and adenocar-
cinoma (Stoler et al., 1992), and it is possible that small early
lesions were not yet apparent on colposcopy and thus not
biopsied. Follow-up of the HPV 18-positive women will help
to clarify this point. The high ratio of low-level to high-level
infections for HPV 18 in this study is not a reflection of any
lack of sensitivity of the primers but may reflect the cut-off
point chosen for evaluation. This was based primarily on the
level of HPV 16 shown to be correlated with high-grade
disease since more data are available for HPV 16.
We have not encountered any problems attributable to
PCR inhibitors in the DNA extracts, as results using P-globin
primers and negative specimens spiked with HPV plasmid
DNA have shown. This may be because the wooden spatula
is discarded after agitation in PBS and the DNA was extract-
ed extensively prior to PCR.
Multiple infections appeared to be more frequent amongst
these patients than in other studies. This may be due to the
use of type-specific primers, which would have a higher
detection rate for multiple types than methods based on a
single amplification with consensus primers.
We have based all our analyses on the 'gold standard' of
histology. It is possible that disease was missed on biopsy in
some cases and could not be visualised on colposcopy in
others. This could have led to an under-representation of
disease, especially low-grade disease, in our series. Further
follow-up will help to resolve this question.
This study suggests that HPV testing may usefully aug-
ment cytology by helping to decide which women with a mild
abnormality need immediate referral. The much larger ques-
tion of the role of HPV testing in routine screening has not
been addressed by this study. Here the problem of specificity
is more acute and any useful addition of cytology will have
to have a low false-positive rate. We have simplified the
DNA extraction procedure without compromising accuracy
(Cuzick et al., 1992b) and adopted microtitre formatted PCR
to address this and other questions in a large-scale ongoing
study.
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